Oligonucleotides
From Design to Delivery – Scientific Depth, Integrated Capability, and Scale Ready Processes
We help organisations accelerate oligonucleotide development with cross-functional, modality-specific support.
From sequence design and impurity control to analytical validation and tech transfer, we provide the chemistry insight and infrastructure you need to move confidently from discovery to clinic.
- Overview
- Oligonucleotide development lifecycle
- Dedicated oligonucleotide infrastructure
- Hybrid modalities and related services
- Why choose us
- In our own words
- FAQs
Oligonucleotides are reshaping therapeutic strategies – from antisense and siRNA to aptamers, CRISPR guides, and mRNA-adjacent platforms. Yet their promise comes with complexity.
With multi-step synthesis, impurity carryover risks, and complex purification requirements, oligo programmes demand deep scientific insight, rigorous analytical control, and scalable infrastructure. Regulatory expectations are rising, and so are the technical barriers.
At CatSci, we partner with innovators at every stage. Whether optimising a novel sequence or scaling a clinical asset, we reduce development risk, improve process reproducibility, and provide the clarity to keep your programme moving. And if your challenge doesn’t fit the standard playbook — from custom linkers to complex modified oligos — we’ll work with you to design a bespoke solution built around your molecule.
Dedicated Infrastructure for Oligonucleotide Development
End-to-End Support, Built Around Your Molecule
By uniting chemistry, analytical science, and bioscience in one seamless workflow, we design and deliver integrated solutions that connect innovation across modalities.
Explore the specialised services that link together across CatSci’s platform.
Why Choose Us
- Decades of oligo expertise integrated with chemistry and analytical platform
- Rigorous impurity mapping, isolation, and characterisation
- Parallelised method transfer and scale-up to shorten timelines
- Seamless integration across discovery, development, and regulatory milestones
Frequently Asked Questions
CatSci offers end-to-end oligonucleotide development services covering design, synthesis, purification, analysis, and regulatory support. Our expertise spans sequence optimisation, impurity control, and analytical validation using LC-MS, IP-RP, and AEX. We help biotech and pharma innovators advance RNA and antisense therapeutics efficiently from discovery to clinic.
Yes. CatSci provides scalable oligonucleotide synthesis and purification, delivering non-GMP gram-scale batches for toxicology and preclinical studies. Using advanced chromatography platforms such as IP-RP and AEX, we achieve high-resolution separation and reliable recovery. Our workflows ensure smooth analytical method transfer and validation readiness for later-phase development.
CatSci’s oligonucleotide development services align with ICH Q14 guidance for method validation and documentation. Every programme includes comprehensive impurity profiling, validated analytical data, and secure tech-transfer packages. This ensures full regulatory compliance, reproducibility, and confidence at each milestone toward clinical manufacture.
Absolutely. We don’t just make oligonucleotides, we solve complex development challenges. Whether you’re working with non-standard linkers, custom reagents, or highly modified backbones, our team thrives on tackling unique, technically demanding projects.
Reach out to our oligonucleotide experts, and we’ll design a tailored solution built around your molecule, your goals, and your timelines.